|
|
Volumn 69, Issue 24, 2012, Pages 2120-
|
|
FDA approves tofacitinib for rheumatoid arthritis
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYTOCHROME P450 3A4;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
METHOTREXATE;
TOFACITINIB;
CELLULITIS;
CYTOMEGALOVIRUS INFECTION;
DIARRHEA;
DRUG APPROVAL;
DRUG LABELING;
DRUG MARKETING;
DRUG SAFETY;
DRUG STORAGE;
ESOPHAGUS CANDIDIASIS;
FOOD AND DRUG ADMINISTRATION;
HEADACHE;
HERPES ZOSTER;
HUMAN;
INFECTION;
KIDNEY DYSFUNCTION;
LATENT TUBERCULOSIS;
LIVER DYSFUNCTION;
LYMPHOMA;
MONOTHERAPY;
NEOPLASM;
NOTE;
OPPORTUNISTIC INFECTION;
PNEUMOCYSTOSIS;
PNEUMONIA;
POLYPHARMACY;
PRIORITY JOURNAL;
RECOMMENDED DRUG DOSE;
RHEUMATOID ARTHRITIS;
RHINOPHARYNGITIS;
RISK FACTOR;
STORAGE TEMPERATURE;
TUBERCULOSIS;
UPPER RESPIRATORY TRACT INFECTION;
URINARY TRACT INFECTION;
|
|
EID: 84872132785
PISSN: 10792082
EISSN: 15352900
Source Type: Journal
DOI: 10.2146/news120088 Document Type: Note |
|
Times cited : (75)
|
|
References (0)
|
